Straits Times Index
3,338.57 +5.77 (+0.17%) S&P 500
5,460.48 -22.39 (-0.41%) Dow
39,118.86 -45.24 (-0.12%) Nasdaq
17,732.60 -126.10 (-0.71%) Bitcoin USD
62,753.17 +1,306.69 (+2.13%) CMC Crypto 200
1,304.19 +2.12 (+0.16%)
Bolt Biotherapeutics, Inc. (BOLT)
After hours:
| Previous close | 0.7476 |
| Open | 0.7500 |
| Bid | 0.7171 x 100 |
| Ask | 0.7748 x 100 |
| Day's range | 0.7313 - 0.7500 |
| 52-week range | 0.7200 - 1.5600 |
| Volume | |
| Avg. volume | 230,504 |
| Market cap | 28.596M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Dev
- GlobeNewswire
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025 REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapi
- GlobeNewswire
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT) in Boston, Massachusetts. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website
